Certain chemotherapy agents, such as anthracyclines (e.g., doxorubicin) and HER2 inhibitors (e.g., trastuzumab), are known to cause a decline in LVEF. These drugs can induce cardiotoxicity, leading to heart failure if not monitored and managed appropriately.
